Netupitant-Palonosetron Combination (NEPA) is a single-day, fixed-dose combination drug that targets dual antiemetic pathways. It is a combination of netupitant, an NK1 receptor antagonist, and palonosetron, a 5-HT3 receptor antagonist. This drug has been used to prevent chemotherapy-induced nausea and vomiting in patients with cancer receiving chemotherapy.